Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent

Endometrial cancer and hyperplasia have long been associated with diabetes. Hyperinsulinemia may have a direct mitogenic effect on the endometrium and may inhibit the effect of progestogen therapy. This case report describes the treatment of a patient with atypical endometrial hyperplasia with an in...

Full description

Saved in:
Bibliographic Details
Published in:Gynecological endocrinology 2003-10, Vol.17 (5), p.405-407
Main Authors: Session, D. R., Kalli, K. R., Tummon, I. S., Damario, M. A., Dumesic, D. A.
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Biological and medical sciences
Endometrial Hyperplasia - drug therapy
Endometrial Hyperplasia - pathology
Endometrium
Female
Gynecology. Andrology. Obstetrics
Humans
Hyperplasia
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - therapeutic use
Insulin
Medical sciences
Metformin
Metformin - administration & dosage
Metformin - therapeutic use
Progestogen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endometrial cancer and hyperplasia have long been associated with diabetes. Hyperinsulinemia may have a direct mitogenic effect on the endometrium and may inhibit the effect of progestogen therapy. This case report describes the treatment of a patient with atypical endometrial hyperplasia with an insulin-sensitizing agent. A 37-year-old patient presented after failed treatment of endometrial hyperplasia with progestogen therapy. One month after initiating metformin therapy the patient's endometrial biopsy demonstrated proliferative endometrium. This patient's atypical endometrial hyperplasia regressed after the initiation of treatment with an insulin-sensitizing agent. This relatively new class of drugs may provide an adjunct to the therapy of endometrial hyperplasia.
ISSN:0951-3590
1473-0766
DOI:10.1080/09513590312331290298